DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Piccart-Gebhart M, Holmes E, Baselga J. et al.
Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial.
J Clin Oncol 2016;
34 (10) 1034-1042
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.